Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study

BACKGROUND: Lorlatinib is a novel potent ALK inhibitor, with only a few studies reporting the results of its clinical use. METHODS: This study describes the outcomes of lorlatinib treatment for 35 non-small cell lung cancer patients with ALK rearrangements, who had 2 (n = 5), 1 (n = 26) or none (n =...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transl Oncol
Main Authors: Orlov, Sergey V., Iyevleva, Aglaya G., Filippova, Elena A., Lozhkina, Alexandra M., Odintsova, Svetlana V., Sokolova, Tatiana N., Mitiushkina, Natalia V., Tiurin, Vladislav I., Preobrazhenskaya, Elena V., Romanko, Alexandr A., Martianov, Alexandr S., Ivantsov, Alexandr O., Aleksakhina, Svetlana N., Togo, Alexandr V., Imyanitov, Evgeny N.
Formato: Artigo
Idioma:Inglês
Publicado em: Neoplasia Press 2021
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8144735/
https://ncbi.nlm.nih.gov/pubmed/34030112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2021.101121
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados